Brexpiprazole
- TRADE NAME: Rexulti (Otsuka)
- INDICATIONS: Schizophrenia, major depressive disorder (with antidepressants)
- CLASS: Antipsychotic
- HALF-LIFE: 86–91 hours
FDA APPROVAL DATE: 07/10/2015
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:Strong or moderate CYP2D6 inhibitors, Strong or moderate CYP3A4 inducers or inhibitors
PREGNANCY CATEGORY: N/A
Neonatal risk in third trimester exposure
INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS and SUICIDAL THOUGHTS AND BEHAVIORS
See full prescribing information for complete boxed warning.
Please login to see the rest of this drug profile
SKIN.
MUCOSAL.
CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
GENITOURINARY.
HEMATOLOGIC.
NEUROMUSCULAR/SKELETAL.
OCULAR.
RESPIRATORY.
OTHER.
Page last updated 11/14/2023
Symbol key
Incidence
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric